Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Incontinence is big business—Boston Scientific valued (PDF) the prosthetic urology and pelvic floor markets at a combined $1.1 billion last year—but could be bigger if more men were aware of ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

With this $3.7-billion acquisition, the company expects to expand its differentiated technologies portfolio within Urology. Boston Scientific is consistently gaining market share within its ...